Entecavir for the treatment of chronic hepatitis B

Draft guidance

Committee papers (PDF 2.24 MB)

Appraisal consultation document (PDF 226 KB)

Hepatitis B - entecavir: review decision - October 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

Hepatitis B - entecavir: review proposal - July 2011 information

Appendix A: provisional matrix of stakeholders (PDF 74 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)

Review decision: June 2009 information

Appendix 1: Proposal comment summary table (PDF 28 KB)

Review proposal: May 2009 information

Review proposal: May 2009, Appendix A - Provisional matrix (PDF 37 KB)

Hepatitis B - entecavir: final appraisal determination

Hepatitis B - entecavir: final appraisal determination information

Hepatitis B - entecavir: final appraisal determination (PDF 89 KB)

Consultee and commentator comments on the ACD

Southampton Health Technology Assessment Group - ERG comments on the BMS Pharmaceuticals Ltd response to the ACD 7 May 2008 (PDF 27 KB)

Southampton Health Technology Assessment Group - part 2 (PDF 13 KB)

Southampton Health Technology Assessment Group - part 1 (PDF 21 KB)

Roche Products (PDF 46 KB)

Gilead Sciences (PDF 24 KB)

Department of Health (PDF 12 KB)

Royal College of Physicians (PDF 24 KB)

Royal College of Nursing (PDF 20 KB)

British Infection Society (PDF 30 KB)

Bristol Myers Squibb (PDF 200 KB)

Expert comments on the ACD

Ms Penny Wilson Webb (PDF 45 KB)

Professor Howard Thomas (PDF 18 KB)

Table of comments on the ACD (PDF 143 KB)

Stakeholders list - final matrix (PDF 41 KB)

Draft scope pre referral (PDF 36 KB)

Provisional matrix pre referral (PDF 38 KB)

Final scope (PDF 40 KB)

Final scope (PDF 40 KB)

Table of comments on matrix (PDF 100 KB)